LMBA02 Protocol for Patients With a Burkitt Lymphoma

To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt lymphoma or ALL 3.

Inclusion Criteria:

• Age : 18 years or older
• Histologically or cytologically proven Burkitt lymphoma according to the WHO classification
• WHO performance < 3
• Informed consent

Exclusion Criteria:

• Known HIV positive infection
• Positive serology for HCV and HBV (except after vaccination)
• Patients previously treated for lymphoma
• cardiac disease that contradict anthracycline chemotherapy
• Psychological or psychiatric condition who contradict steroids therapy
• Patients with serious renal failure unrelated to the lymphoma (serum creatinin level higher than 150 mmole/L)
• Cirrhosis or severe hepatic failure unrelated to the lymphoma
• Previous malignant disease except basal cell skin carcinoma or in situ uterine cervix carcinoma
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
• Primary organ transplant or other immunosuppressive conditions Pregnancy